BRIEF published on 04/22/2026 at 22:05, 18 days 9 hours ago Inventiva strengthens its leadership for phase 3 of lanifibranor Appointment Biopharmaceutical Direction Phase 3 Lanifibranor
BRIEF published on 04/22/2026 at 22:05, 18 days 9 hours ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
PRESS RELEASE published on 04/22/2026 at 22:00, 18 days 9 hours ago Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor Inventiva strengthens leadership team with new key hires for lanifibranor Phase 3 data readout, bolstering expertise in finance, legal, and HR to drive growth and commercialization Growth Leadership Team Phase 3 Inventiva Lanifibranor
BRIEF published on 04/08/2026 at 22:05, 1 month 2 days ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
BRIEF published on 04/08/2026 at 22:05, 1 month 2 days ago Inventiva files its Universal Registration Document and its 2025 Annual Report Annual Report Biopharmaceutical Registration Document Inventiva MASH
PRESS RELEASE published on 04/08/2026 at 22:00, 1 month 2 days ago Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Inventiva files 2025 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, focusing on MASH therapies Biopharmaceutical 2025 Filing Inventiva MASH
BRIEF published on 04/02/2026 at 15:55, 1 month 8 days ago JP Morgan Chase & Co. crosses the thresholds for participation in INVENTIVA Voting Rights Threshold Crossing JP Morgan Inventiva Equity Swap
BRIEF published on 03/30/2026 at 22:16, 1 month 11 days ago Inventiva Announces 2025 Financial Results and Business Update Public Offering Cash Reserves Inventiva Lanifibranor 2025 Financial Results
PRESS RELEASE published on 03/30/2026 at 22:11, 1 month 11 days ago Inventiva reports 2025 full year results and provides a business update Inventiva reports 2025 full year results with €4.5 million revenues, provides business update on strategic pipeline, clinical trials, and financial performance Financial Performance Business Update Clinical Trials Inventiva 2025 Results
BRIEF published on 03/23/2026 at 22:05, 1 month 18 days ago Inventiva Announces Schedule for 2025 Financial Results Financial Results Conference Call Biopharmaceutical Inventiva MASH
Published on 05/09/2026 at 01:30, 2 days 5 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 7 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/11/2026 at 07:00, 16 minutes ago Aurubis AG: Aurubis delivers improved performance: Increased quarterly result and higher forecast
Published on 05/11/2026 at 07:00, 17 minutes ago 3U HOLDING AG awarded DGNB Gold Certificate for its new headquarters in Marburg
Published on 05/10/2026 at 16:05, 15 hours 11 minutes ago RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 17 hours 16 minutes ago MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/07/2026 at 19:15, 3 days 12 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:06, 3 days 12 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 18:17, 3 days 13 hours ago DESCRIPTION OF THE LOUIS HACHETTE GROUP SHARE BUYBACK PROGRAM 2026-2027
Published on 05/07/2026 at 17:45, 3 days 13 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
